GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RaQualia Pharma 4579.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

650

+13.44%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About RaQualia Pharma

Its shares trade on Tokyo Stock Exchange under the ticker 4579.T. It has been listed since 20 July 2011. In the fiscal year to 31 December 2025, it reported revenue of ¥3.98bn and net income of ¥273.1m. At that date it held total assets of ¥10.51bn and shareholders' equity of ¥6.90bn.

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
20 Jul 2011
Employees
65

Leadership

Pay as last reported

  • Mr. Katsuhiro UtoExecutive Officer, Director, since 2021
  • Mr. Kaoru ShimadaExecutive Officer
  • Mr. Masaki SudoRepresentative Director, since 2021
  • Mr. Kosuke IshiiIndependent Director
  • Mr. Yuichi KakinumaIndependent Director
  • Mr. Takayuki TanakaIndependent Director
  • Mr. Michihiro TsuchiyaIndependent Director
  • Mr. Hideshi SugiyamaDirector of Accounting and Finance, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Nagoya, Aichi-Ken with 65 employees
  • Focus on pain and intestinal disease areas for drug development
  • Engaged in R&D, preclinical trials, and partial clinical trials

Weaknesses

  • Limited to specific disease areas of pain and intestinal diseases
  • Relies on licensing developed compounds to other pharmaceutical companies
  • No mention of commercialized products or revenue streams

Opportunities

  • Expansion into new disease areas beyond current focus
  • Potential for increased partnerships with pharmaceutical companies
  • Growth in pharmaceutical R&D market

Threats

  • Dependence on licensing for revenue generation
  • Competition in pharmaceutical R&D sector
  • Risk of failure in drug development and clinical trials

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.